Suppr超能文献

坦索罗辛与西洛多辛在计划进行无导尿管试验的良性前列腺增生继发急性尿潴留患者管理中的比较。一项前瞻性随机研究。

Comparison of tamsulosin and silodosin in the management of acute urinary retention secondary to benign prostatic hyperplasia in patients planned for trial without catheter. A prospective randomized study.

作者信息

Patil Siddangouda B, Ranka Kshitiz, Kundargi Vinay S, Guru Nilesh

机构信息

Department of urology, BLDEU'S Shri B.M. Patil Medical College, hospital and research centre, Bijapur, India.

出版信息

Cent European J Urol. 2017;70(3):259-263. doi: 10.5173/ceju.2017.1313. Epub 2017 Jun 29.

Abstract

INTRODUCTION

We present a prospective randomized study to compare the efficacy of tamsulosin and silodosin in patients suffering from acute urinary retention caused by benign prostatic hyperplasia, planned for trial without catheter.

MATERIAL AND METHODS

Patients with acute urinary retention secondary to benign prostatic hyperplasia (total 160) were catheterized and randomized into two groups: Group A: tamsulosin 0.4 mg (80 patients) and Group B: silodosin 8 mg (80 patients). After three days, the catheter was removed, and patients were put on trial without catheter. Patients with a successful trial without catheter were followed up after two weeks and one month, taking into account the international prostate symptom score (IPSS), post void residual volume (PVR), and peak flow rate (PFR). Statistical analysis of the data was performed.

RESULTS

Both group A (tamsulosin) and group B (silodosin) had similar results of trial without catheter (group A: 67.50%, group: B 60%). In follow up, three patients in group A and four patients in group B had retention of urine, requiring recatheterization. These patients were withdrawn from the study. No significant differences were present between group A and group B patients in regard with IPSS, PVR and PFR measured at the time of successful trial without catheter and during follow up at two weeks and one month.

CONCLUSIONS

Efficacy for trial without catheter of tamsulosin was slightly higher than silodosin, but comparable. No statistical difference between tamsulosin & silodosin treated groups were found in regard with IPSS, PVR and PFR.

摘要

引言

我们开展了一项前瞻性随机研究,以比较坦索罗辛和西洛多辛在因良性前列腺增生导致急性尿潴留且计划无导尿管试验的患者中的疗效。

材料与方法

将继发于良性前列腺增生的急性尿潴留患者(共160例)插入导尿管并随机分为两组:A组:坦索罗辛0.4毫克(80例患者)和B组:西洛多辛8毫克(80例患者)。三天后,拔除导尿管,患者进行无导尿管试验。无导尿管试验成功的患者在两周和一个月后进行随访,记录国际前列腺症状评分(IPSS)、排尿后残余尿量(PVR)和最大尿流率(PFR)。对数据进行统计分析。

结果

A组(坦索罗辛)和B组(西洛多辛)无导尿管试验结果相似(A组:67.50%,B组:60%)。随访中,A组有3例患者和B组有4例患者出现尿潴留,需要重新插入导尿管。这些患者退出研究。在无导尿管试验成功时以及两周和一个月随访时测量的IPSS、PVR和PFR方面,A组和B组患者之间无显著差异。

结论

坦索罗辛无导尿管试验的疗效略高于西洛多辛,但具有可比性。在IPSS、PVR和PFR方面,坦索罗辛治疗组和西洛多辛治疗组之间未发现统计学差异。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验